Taysha Gene Therapies Inc.
TSHA | NASDAQ
$5.14
+$0.10 (+1.98%)
Sep 22, 2026, 2:14 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 9.77M | 8.33M | 15.45M | 2.5M | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 2.49M | n/a | 9K |
Gross Profit | 9.77M | 8.33M | 15.45M | 15K | n/a | -9K |
Operating Income | -110.5M | -91.46M | -72.44M | -126.03M | -173.27M | -43M |
Interest Income | 9.22M | 6.94M | 3.57M | 249K | 172K | 49K |
Pretax Income | -109M | -89.3M | -111.57M | -166.01M | -174.52M | -60.01M |
Net Income | -109M | -89.3M | -111.57M | -166.01M | -174.52M | -43M |
Selling & General & Admin | 33.87M | 28.95M | 30.05M | 34.87M | 41.32M | 11.1M |
Research & Development | 86.4M | 66M | 56.78M | 91.17M | 131.94M | 31.89M |
Other Expenses | n/a | 4.84M | 1.07M | n/a | n/a | n/a |
Operating Expenses | 120.27M | 99.79M | 87.89M | 126.04M | 173.27M | 42.99M |
Interest Expense | 63K | 102K | 5M | 3.8M | 1.43M | 28K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 120.27M | 99.79M | 87.89M | 128.53M | 173.27M | 43M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M |
Shares Outstanding (Diluted) | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M |
EPS (Basic) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
EPS (Diluted) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
EBITDA | -107.79M | -87.95M | -105.2M | -159.73M | -172.6M | -59.97M |
EBIT | -108.93M | -89.2M | -106.57M | -162.22M | -173.1M | -59.98M |
Depreciation & Amortization | 1.15M | 1.25M | 1.37M | 2.49M | 492K | 9K |
Add to Watchlist
Select watchlists to add or remove TSHA